




RealRate

PHARMACEUTICAL 2019

Adhera Therapeutics Inc.
Rank 361 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2019

Adhera Therapeutics Inc.
Rank 361 of 371



The relative strengths and weaknesses of Adhera Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adhera Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 470% points. The greatest weakness of Adhera Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 1,012% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,762%, being 1,431% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	4,677
Cost of Goods Sold	459
Intangible Assets	392
Liabilities, Current	2,214
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	9,142
Other Liabilities	0
Other Net Income	-960
Property and Equipment	72
Research and Development	241
Revenues	76
Selling, General and Administrative Expense	6,029

Output Variable	Value in 1000 USD
Assets	5,141
Liabilities	2,214
Expenses	15,871
Stockholders Equity	2,927
Net Income	-16,755
Comprehensive Net Income	-16,755
Economic Capital Ratio	-1,762%

